Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm Patients
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Irinotecan
Related studies linked through entity extraction aliases.
SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patients
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 Type
- Status
- UNKNOWN
- Phase
- PHASE2
Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study
- Status
- COMPLETED
- Phase
- PHASE3
DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Comparison of Interleukin-11 and rhTPO for Recurrent Colorectal Cancer Patients With Thrombocytopenia
- Status
- UNKNOWN
- Phase
- PHASE2
Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas
- Status
- COMPLETED
- Phase
- PHASE2
Intraperitoneal and System Chemotherapy Versus XELOX as First-line Chemotherapy for mCRC
- Status
- UNKNOWN
- Phase
- PHASE2
FOLFIRINOX for 2nd-line Treatment of BTC
- Status
- COMPLETED
- Phase
- PHASE2
Irinotecan-based Triplet (FOLFOXIRI) as Perioperative Treatment in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal
- Status
- UNKNOWN
- Phase
- PHASE2
Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients
- Status
- COMPLETED
- Phase
- PHASE2
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
- Status
- RECRUITING
- Phase
- PHASE1